These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9436456)

  • 1. [Molecular pathology of malignant hyperthermia and central core disease].
    Takagi A
    Nihon Rinsho; 1997 Dec; 55(12):3307-14. PubMed ID: 9436456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores.
    Quane KA; Keating KE; Healy JM; Manning BM; Krivosic-Horber R; Krivosic I; Monnier N; Lunardi J; McCarthy TV
    Genomics; 1994 Sep; 23(1):236-9. PubMed ID: 7829078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia.
    Quane KA; Healy JM; Keating KE; Manning BM; Couch FJ; Palmucci LM; Doriguzzi C; Fagerlund TH; Berg K; Ording H
    Nat Genet; 1993 Sep; 5(1):51-5. PubMed ID: 8220423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mutation in the human ryanodine receptor gene associated with central core disease.
    Zhang Y; Chen HS; Khanna VK; De Leon S; Phillips MS; Schappert K; Britt BA; Browell AK; MacLennan DH
    Nat Genet; 1993 Sep; 5(1):46-50. PubMed ID: 8220422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic analysis with calcium-induced calcium release test in Japanese malignant hyperthermia susceptible (MHS) families.
    Maehara Y; Mukaida K; Hiyama E; Morio M; Kawamoto M; Yuge O
    Hiroshima J Med Sci; 1999 Mar; 48(1):9-15. PubMed ID: 10213958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in RYR1 in malignant hyperthermia and central core disease.
    Robinson R; Carpenter D; Shaw MA; Halsall J; Hopkins P
    Hum Mutat; 2006 Oct; 27(10):977-89. PubMed ID: 16917943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.
    Murayama T; Kurebayashi N; Ogawa H; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    Hum Mutat; 2016 Nov; 37(11):1231-1241. PubMed ID: 27586648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
    Monnier N; Lunardi J
    Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization.
    Guis S; Figarella-Branger D; Monnier N; Bendahan D; Kozak-Ribbens G; Mattei JP; Lunardi J; Cozzone PJ; Pellissier JF
    Arch Neurol; 2004 Jan; 61(1):106-13. PubMed ID: 14732627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease.
    Lyfenko AD; Goonasekera SA; Dirksen RT
    Biochem Biophys Res Commun; 2004 Oct; 322(4):1256-66. PubMed ID: 15336973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant hyperthermia and excitation-contraction coupling.
    Melzer W; Dietze B
    Acta Physiol Scand; 2001 Mar; 171(3):367-78. PubMed ID: 11412150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the number of diagnostic mutations in malignant hyperthermia.
    Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
    Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ca2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations.
    Brini M; Manni S; Pierobon N; Du GG; Sharma P; MacLennan DH; Carafoli E
    J Biol Chem; 2005 Apr; 280(15):15380-9. PubMed ID: 15689621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutated p.4894 RyR1 function related to malignant hyperthermia and congenital neuromuscular disease with uniform type 1 fiber (CNMDU1).
    Haraki T; Yasuda T; Mukaida K; Migita T; Hamada H; Kawamoto M
    Anesth Analg; 2011 Dec; 113(6):1461-7. PubMed ID: 21926372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant hyperthermia and central core disease causative mutations in Swedish patients.
    Broman M; Islander G; Müller CR; Ranklev-Twetman E
    Acta Anaesthesiol Scand; 2007 Jan; 51(1):50-3. PubMed ID: 17081152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombination between the postulated CCD/MHE/MHS locus and RYR1 gene markers.
    Fagerlund TH; Islander G; Ranklev-Twetman E; Berg K
    Clin Genet; 1996 Dec; 50(6):455-8. PubMed ID: 9147872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ryanodine receptors.
    Ogawa Y
    Crit Rev Biochem Mol Biol; 1994; 29(4):229-74. PubMed ID: 8001396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What significance to genotype changes have in diagnosis of malignant hyperthermia?].
    Steinfath M; Scholz J; Singh S; Wappler F
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Aug; 31(6):334-43. PubMed ID: 8962927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Genet Test; 2003; 7(3):203-11. PubMed ID: 14641996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.